TransThera seeks Hong Kong IPO to sustain cancer drug research
The developer of drugs for advanced or recurrent cancers has already conducted nine financing rounds, but will not start generating commercial revenue before 2026, as all its products are still…
Recent Articles
RELATED ARTICLES
-
Akeso marks profit milestone with swift rights issue
9926.HK -
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
- Sunho Biologics gets green light for downsized IPO
- InSilico seeks IPO boost to get AI drugs over the line
-
RemeGen hopes for pain relief from expanded drug uses
9995.HK 688331.SHG
